Note: Descriptions are shown in the official language in which they were submitted.
WO 95/09601 ~ 2 1 7 3 1 0 ~ PCTIUS94/10~04
Use of azithromycir for the treatment of adult periodontit~s
and top~cal compositions for th~s use
Technical Field
This invention involves a novel use of azithromycin for treating adult
periodontitis.
Backqround Of The Invention
Periodontal disease comprises a group of inflammatory conditions of
periodontal tissues with a common etiologic agent: bacteria in the form of
dental plaque. Periodontal disease is the most frequent cause of tooth loss in
adults. After 40 years of age, the majority of the population exhibits some signof periodontitis. Periodontitis develops following plaque accumulation and will
not develop in the absence of plaque. If plaque is present, the bacteria
metabolize and produce acids and toxins which can irritate the gums and
cause gingival inflammation, gingivitis. Although not all gingivitis sites in the
presence of plaque develop loss of connective tissue attachment and/or
alveolar bone resorption (a disease called periodontitis) all periodontitis is
preceded by gingivitis. Although it is unknown what triggers the conversion
from gingivitis to periodontitis, it could be bacterial accumulation due to poororal hygiene, or systemic factors, or a combination of these.
Tissue destruction may occur as a slow continuous process, or as the
result of repeated episodes of active disease alternating with intervals of
disease remission and repair. An individual may have sites within his or her
mouth which are healthy and others which have varying stages of disease
coexisting.
There are several different forms of periodontitis in humans. The
distinct diseases may have different etiologies and are likely to progress and
respond differently to a given therapy.
Common adult periodontitis is the most common form of periodontitis
and typically does not appear until a subject is 35 years of age or older. It ispreceded by gingivitis and the establishment of a pathogenic subgigival
microflora. The presence of microbial deposits and calculus is usually
commensurate with the amount of periodontal destruction. When host
defenses are insufficient, specific pathogens in the subgingival microflora willincrease and cause tissue breakdown. The subgingival microflora in
periodontitis is very complex microbiota with elevated proportions of motile,
gram-negative, capnophilic and anaerobic species. There are specific
microorganisms that appear to be more strongly associated with these lesions.
WO 95/09601 ', r ~ 2 1 7 3 1 0 9 PCT/U594/10804
The main microorganisms associated with adult periodontitis are:
Porphyromonas gingivalis, Prevotella intermedia; Eikenella corrodens,
Fusobacterium nucleafum; Wolinella recta; Selenomonas sputigena;
Eubacterium timidum, Eubacterium brachyii, Peptosteptococcus micros; and
spirochetes, including Treponema denticola.
Rapidly progressive periodontitis is a clinical condition which affects
yound adults (20-35 years of age) with generalized sever and rapid bone loss.
Overt clinical inflammation is not always seen. Small amounts of plaque and
calculus may be present. The lesions are associated with elevated
proportions of Porphyromonas gingivalis, Bacteroides capillosus, Prevotella
intermedia, Bacteroides forsythus, Actinobacillus species, Eikene~la corrodens,
and Wolinella recta either individually or in different patterns.
Refractory adult periodontitis refers to periodontal lesio1s or clinical
conditions which are refractory (unresponsive) to periodontal tr~atment. The
microflora of these lesions are Actinobacillus actinomycetemcomitans (A.a.),
Porphyomonas gingivalis and Prevotella intermedia. It has been theorized that
this group of pathogens is reponsible for this clinical condition.
Juvenile periodontitis typically has an onset age around the age of
puberty of a subject. The disease manifests itself as inflammation and rapid
destruction of the peridontal tissues around more than one tooth in the
permanent dentition. These lesions progress rapidly after onset but tend to
slow with time. There is often (not always) a small amount of supragingival
plague and calculus which is not commensurate with the amount of destruction
present. A.a. is the most frequently isolated species frorn subgingival
microflora of sites experiencing disease. However, some subgingival
pathogens isolated have also been found in elevated proportion in these
lesions, including Eikenella corrodens, Fusobacterium nucleatum, Bacteroides
capillosus and Eubacterium brachyii.
Prepubertal periodontits has its onset during or immediately following
eruption of primary teeth (4-8 years of age). This disease typically manifests
itself as a very severe and rapid peridontal destruction around the primary
teeth. A.a. is the most prominent pathogen frequently associated with other
microorganisms such as Selenomonas sputigena, Prevotella intermedia, and
Eikenella corrodens.
Although some antibiotics are known to be useful in the treatment of
adult periodontitis, not all are useful for such therapy. Some, such as
tetracycline, tend to encourage the production of resistant strains of bacteria.Some antibiotics, those not having a long half-life, require multiple dosages
per day to achieve efficacy. This is not very conducive to consistant
WO 9StO9601 . . ~ r ~ 2 t 7 3 1 0 9 PCTIUS9411080~
compliance by the patient. Some antibiotics can cause systemic
complications, such as stomach upset and nausea.
Applicant has surprisingly discovered that compositions and methods of
this invention using azithromycin are safe and effective for the treatment of
5 adult periodontitis. Methods of this invention afford efficacy greater than
methods among those described in the art. Azithromycin can be delivered
perorally, systemically, or topically in the oral cavity.
Summarv Of The Invention
This invention relates to methods for treatment of adult periodontitis in a
10 human or other animal subject, comprising administering to the subject having such disease a safe and effective amount of azithromycin.
This invention also relates to compositions for use in such treatment.
Detailed Description Of The Invention
"Periodontal pocket" as used herein, means an abnormally deep
15 gingival sulcus, which is due to the apical migration of the gingival attachment,
associated with periodontitis.
"Periodontal disease" as used herein, means, those diseases which
attack the gingiva and the underlying alveolar bone supporting the teeth.
Periodontal disease includes gingivitis (inflammation of the gums), and all
20 forms of periodontitis, as well as series of oral diseases exhibiting varioussyndromes which vary from each other according to the stage or situation of
the disease or the age of the patient, and have not been definitely
subclassified.
"Adult periodontitis" as used herein, refers to the forms of periodontitis
25 typically associated with Porphyromonas gingivalis bacterium, and whose age
of onset is about 20 years of age or older; such diseases can include common
adult periodontitis, refractory adult periodontitis, and rapidly progressive
periodontitis. Adult periodontitis is a condition whose predominant putative
ediologic agent is not Actinobacillus actinomycetemcomifans ("A.a."). "A.a.-
30 associated periodontitis" refers to the clinical conditions of periodontitis whosepredominant putative ediologic agent is the bacterium, A.a.; such clinical
conditions can include juvenile periodontitis and prepubertal periodontitis.
This invention involves methods for treatment of adult periodontitis in a
human or other animal subject, comprising administering to the subject having
35 such disease a safe and effective amount of azithromycin. As used herein
"safe and effective amount" means an amount of compound or composition
sufficient to significantly induce a positive modification in the condition to be
treated, but low enough to avoid serious side effects (at a reasonable
benefit/risk ratio), within the scope of sound medical judgment. The safe and
WO 95/09601 ~ i C 2 1 7 3 1 0 9 PCT/US94/10804
effective amount of the compound or composition will vary withlthe particular
condition being treated, the age and physical condition of the patient being
treated, the severity of the condition, the duration of the treatm~nt, the nature
of concurrent therapy, the specific compound or composition f~mployed, the
particular pharmaceutically-acceptable carrier utilized, and like factors withinthe knowledge and expertise of the attending health care provider.
Azithromycin, (2R,3S,4R,5R,8R, 1 OR, 1 1 R, 1 2S, 1 3S, 1 4R)-13-[(2,6-
Dideoxy-3-C-methyl-3-0-methyl-a-L-ribo-hexopyranosyl)oxy]-2ethyl-3,4, 1 O-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-1 1-[[3,4,6-trideoxy-3-(dimethylamino)-
10 b-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one is disclosed
in the MERCK INDEX, 11th ed. (1989), S. Budavari, ed., No. 928, p. 146.
Azithromycin is also described in U.S. Pat. No. 4,517,359, the disclosure of
which is incorporated herein by reference. Also suitable for use in this
invention are pharmaceutically-acceptable salts of azithromycin, including but
15 not limited to the hydrochloride, tartrate, malate, malic, acetate, and sulfate
salts. I
Treatments of adult periodontitis utilizing ~cilhrorl~ycin therapy may be
achieved by delivering azithromycin systemically, e.g. through peroral dosage,
or achieved through sustained release drug delivery, or achieved topically.
ComPositions
Dose forms suitable for use in this invention includel those which
provide systemic delivery of azithromycin. Systemic dosage forrns may be any
form suitable and safe for human systemic administration, such as tablets,
capsules, suspensions, injectable solutions, and other typical systemic dose
25 forms well known in the field.
Peroral dosage compositions useful in the methods of this invention are
preferably provided in unit dosage form. As used herein, a "unit dosage form"
is a composition of this invention containing an amount of drug, i.e.
a~iLhromycin or a pharmaceutically-acceptable salt thereof, thatl is suitable for
30 admir,listration to a human or other animal subject, in a single dose, according
to good medical practice. These compositions preferably contain from about
10 mg (milligrams) to about 1,000 mg, more preferably from about 100 mg to
about 750 mg, more preferably from about 250 mg to about 500lmg, also more
preferably, from about 300 to about 400 mg of azithromycin or a
35 pharmaceutically-acceptable salt thereof.
A variety of pharmaceutically-acceptable gastric delivery carriers well-
known in the art may be used. These include solid or liquid f!llers, diluents,
hydrotropes, surface-active agents, and encapsulating substances. The
amount of carrier employed in conjunction with the azithromycin is sufficient to
WO 95/09601 ~ ` t . .~ 2 1 73 1 D~ PCTIUS94110804
provide a practical quantity of material ;for administration per unit dose.
Techniques and compositions for making dosage forms useful in the methods
of this invention are described in the following references, each incorporated
by reference herein: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker &
5 Rhodes, editors, 1979); Lieberman et al., Pharmaceutical Dosaqe Forms:
Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosa~e Forms 2d
Edition (1976).
Various oral dosage forms can be used, including such solid forms as
tablets, capsules, granules, and bulk powders. These oral forms comprise a
10 safe and effective amount, usually at least about 5%, and preferably from
about 25% to about 50%, of azithromycin or a pharmaceutically-acceptable
salt thereof. Tablets can be compressed, tablet triturates, enteric-coated,
sugar-coated, film-coated, or multiple-compressed, containing suitable
binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring15 agents, flow-inducing agents, and melting agents. Liquid oral dosage forms
include aqueous solutions, emulsions, suspensions, solutions and/or
suspensions reconstituted from non-effervescent granules, and effervescent
preparations reconstituted from effervescent granules, containing suitable
solvents, preservatives, emulsifying agents, suspending agents, diluents,
20 sweeteners, melting agents, coloring agents and flavoring agents. Capsules
are presently available under the trade name ZithromaxTM and provided by
Pfizer Inc.
Other dose forms useful in this invention include "sustained release oral
drug delivery systems" which can provide sustained release of a drug topically
25 in or around a periodontal lesion such as a periodontal pocket. Preferred
compositions of this invention for use in treatment of adult periodonlilis in a
human or other animal subject comprise comprise: a) a safe and effective
amount of azithromycin or a pharmaceutically-acceptable salt thereof; and b) a
sustained release oral drug delivery system. Such sustained release oral drug
30 delivery systems may utilize non-bioerodible, biocompatible polymers capable
of being formed into a solid, such as those described in U.S. Pat. No.
5,114,718, issued May 19, 1992 to Damani, incorporated herein by reference.
Such polymers may include polyurethanes, collagen, polyacrylates,
elastomeric copolymers (including polyisobutylene and ethylene vinyl ~cet~te
35 copolymers), cellulosic polymers (including hydroxymethyl cellulose,
hyroxyethyl cellulose, hydroxypropyl cellulose, hydroxybutyl cellulose and
esters such as cellulose acetate and cellulose acetate phthalate), ethylene
vinyl alcohol copolymers, polystyrene, polyvinyl chloride, polycarbonate, and
polyethylene among many others. Preferred polymers are ethylene vinyl
WO95/09601 ~ 2 1 7 3 1 0 9 I'CT/US94/10804
acetate, polyisobutylene and polyurethane with ethylene vinyl acetate being
the preferred material.
Sustained release oral drug delivery systems may also utilize
bioerodible polymers such as those described in U.S. Pat. 5,198,220, issued
Mar. 20, 1993 to Damani, and in U.S. Pat. No. 5,173, 299, issued Dec. 22,
1992 to Damani, both incorporated herein by reference. Other bioerodible
polymers useful in this invention include those polymer materials which are
safe for use in the oral cavity of a human or other animal, which are solubilized
or plasticized by inclusion of leachable solvents and thereby hardened upon
placement of compositions containing the polymer into the periodontal tissue,
and which slowly degrade in the periodontal tissue. Such polymers are known,
including for example polymers and copolymers such as glycerides,
polyacrylates, polylactic acid ("PLA"), polyglycolic acid (''PLG''),I polylactyl-co-
glycolic acid ("PLGA"), polyaminoacids such as polyaspartate, chitosan,
collagen, polyalbumin, gelatin, hydrolyzed animal protein, alginilc acid and itsderivatives, xanthan and other water soluble gums, polyanhydride, and poly
orthoesters. Preferred are polymers and copolymers of polylactic acid ("PLA"),
polyglycolic acid ("PLG"), and polylactyl-co-glycolic acid ("PLGA").
Preferred bioerodible polymers useful for this invention are the
copolymers containing mixtures of lactide and glycolide monomers. Lactide
monomeric species preferably comprise from about 15% to about 85%, most
preferably from about 35% to about 6~% of the polymers, while glycolide
monomeric species comprise from about 15% to about 85% o' the polymer,
preferably from about 35% to about 65% on a molar basis. ~he molecular
weight of the copolymer typically lies in the range of from about l1000 to about120,000 (number average). These polymers are described in detail in U.S.
Patent 4,443,430, April 17, 1984, to Mattei incorporated herein by reference.
The feature of fluid gel or paste-like compositions containing such
copolymers is their transformation into near solid phase in the presence of
aqueous fluid such as water, aqueous buffers, serum, crevicular fluid, or other
body fluid. For example, when a sample of such a gel is placed into a tube
containing water or human serum, the composition becomes neqrly solid in the
receptor phase. Thus, even though such fluid compositions can be used
advantageously when desired from a syringe-like apparatus, they still offer the
uncompromised advantages of solid devices at the treatment sites. Further,
since such polymeric materials do undergo slow degradatlon, the drug
continues to release in a sustained manner from such compositions and the
composition does not need to be surgically removed fo!lowing tissue
regeneration.
WO 95/09601 ~ ~ ~ ; ;. - 2 1 7 3 1 0 9 PCTIUS94/10804
Conventional methods and apparatuses may be used to formulate
compositions of this invention~ Combinations of polymers may be used. The
polymers generally comprise from about 1% to about 90%, preferably from
~, about 10% to about 70%, of the compositions/devices useful for the methods
5 of this inventions. Generally, for the most preferred copolymers containing
lactide and glycolide, less polymer is necessary as the amount of lactide is
increased.
The amount of azithromycin used in sustained release oral drug
delivery compositions of this invention may be from about 0.5% to about 95%
preferably from about 5% to about 50%, more preferably from about 10% to
about 35% by weight of the composition. The compositions/devices may be
designed to release azithromycin to provide a minimum concenl~lion of active
drug of from about 1~Jg per milliliter crevicular fluid up to about 5000 ~Jg permilliliter, more preferably from about 5 ,ug per milliliter to about 100 ~9 per
milliliter crevicular fluid. One l~g per milliliter crevicular fluid is substantially
equivalent to 1 ,ug per gram gingiva.
Other dose forms suitable for use in this invention include traditional
oral care compositions comprising a "pharmaceutically-acceptable topical oral
carrier", as used herein, denotes a carrier for the active compound of this
invention comprising solid or liquid filler diluents suitable for use in contactwith the oral tissues of humans and lower animals without undue toxicity,
incompatibility, instability, irritation, allergic response, and the like,
commensurate with a reasonable benefit/risk ratio. Such topical oral carrier,
when combined with an active of this invention, results in a composition which
is administered topically to the oral cavity. Preferably such compositions are
held in the oral cavity for a period of time, and then largely expectorated rather
than being swallowed. Such compositions include dentifrice, toothpaste,
mouthwash, mouth rinse, and dental rinse, chewing gum, and lozenge carriers.
Preferred topical oral compositions of this invention for use in treatment
of adult periodontitis in a human or other animal subject comprise: a) a safe
and effective amount of azithromycin or a pharmaceutically-accep~able salt
thereof; and b) a pharmaceutically-acceptable topical oral carrier.
Components of such compositions and topical oral carriers are described in
U.S. Patent No. 4,994,262 issued Feb. 19, 1991, to Charbonneau et al., and in
U.S. Pat. No. 4,990,329, issued Feb. 5, 1991, to Sampathkumar; both
incorporated herein by reference.
If incorporated into a topical oral carrier, the ~ romycin would be
present at from about 0.01% to about 2% more preferably from about 0.1% to
about 1%, more preferably still from about 0.1% to about 0.5% of a liquid
WO9S/09601 . ~ C 2 1 73 1 09 P~ S94/10804
carrier, such as a mouthwash, or a dental rinse. If incorporated into a
dentifrice topical oral carrier, the azithromycin would be present qt from about0.1% to about 20%, more preferably from about 1% to about 10%, more
preferably still from about 15% to about 5%.
Methods of Use
This invention also relates to methods for treatme;nt of adult
periodontitis in a human or other animal subject, comprising administering to
the subject having such disease a safe and effective amount of a~ lhromycin.
Systemic dosage forms may be any form suitable and safe for human
systemic administration, such as tabletc capsules, suspensions, injectable
solutions, and other typical systemic dose forms well known in the field.
Capsules are presently available under the trade name ZithromaxTM and
provided by Pfizer Inc.
Typically, the peroral dosage amounts of azithromycin may be from
about 10 mg to about 1000 mg per dose, preferably from aboyt 100 mg to
about 750 mg, also more preferably still from about 250 mg to about 500 mg,
also more preferably from about 300 mg to about 400 mg a~ill,ro"lycin. A
dose is taken preferably from once every other day to about four times per
day, more preferably from about once per day to about twice per day, more
preferably once per day. More preferred still is a 500 mg dose once on a first
day and a 250 mg dose once per day thereafter for from about 5 qays to about
30 days, more preferably from about 5 days to about 10 days. r,eferably no
more than about 1000 mg a~ilhro~"ycin is ingested in any giv~ n day; more
preferably, no more than about 500 mg is ingested in one day.
Sustained release compositions are administered by gently placing the
product in subgingival cavities of infected teeth. If the composition is one
which hardens when inserted into the gingival pocket, the composition may be
administered with a syringe or like apparatus fitted with a needle or catheter.
The composition is injected into or near the base of the pocket; the syringe tipis slowly withdrawn as the pocket is filled. If the composition is one which is
solid when inserted, the composition may be inserted into the pocket using
dental instruments, including but not limited to, cotton pliers, forceps, a
refraction cord, and plastic instruments. A solid composition may be trimmed
with a scalpel or other sharp instrument to fit a subgingival cavity before
insertion. Depending on the size of the periodontal pocket into which
sustained release drug delivery system is being inserted, from about 0.05 mL
to about 2 mL, preferably from about 0.1 mL to about 1 mL of composition is
used. If the composition is non-bioerodible, it should be removed from about
;
WO95/09601 ~ . 2 1 7 3 1 ~9 PCTIUS94J108~4
~ . .
seven to about fourteen days after insertion. If the composition is bioerodible
there should be no need to remove the composition after insertion.
If a topical oral carrier is used to deliver azithromycin, the compositions
may be utilized in conventional fashion, preferably from about once weekly to
5 about three times daily, more preferably from about twice weekly to about
twice daily, more preferably still from about once daily to about twice daily.
EXAMPLES
The following non-limiting exampies further describe and demonstrate
preferred embodiments within the scope of the invention. The examples are
10 given solely for illustration and are not to be construed as limitations of this
invention, as many variations are possible without departing from the spirit andscope of the invention.
The compositions of this invention can be made using methods which
are commonly used to produce oral care products.
ExamPle I
The following is a representative example of a a syringeable gel composition.
comPonent % wt of comPosition
Azithromycin 2~
gliycerol monooletate 70
20 Hydroxypropyl methylcellulose 5
Glycerol monooleate is heated to about 60C. Hydroxypropyl
methylcellulose is dispersed with agitation to uniformity. Azythromycin is
mixed at about 40C to uniformity and the mixture is cooled to room
temperature.
0.1 mL of the gel is applied by injecting the gel into the base of a
gingival pocket with a syringe fitted with a needle. The syringe tip is withdrawn
as the pocket is filled. Once inserted, the composition undergoes a phase
transition to cubic crystalline phase with increased viscosity. The sustained
release drug delivery system is removed after ten days. The result is red~ ~ced
gingival inflammation and a decrease in pocket depth.
Example ll
The following is a representative example of a sustained release composition
for insertion into a peridontal pocket.
ComPonent % wt of composition
Polylactic-glycolic acid 64
Azythromycin 30
Propylene carbonate 6
The polylactic acid polymer having an average molecular weight of
about 4000 is blended with azythromycin. Propylene carbonate, a plasticizer,
WO 95/09601 ~ 2 ~ 7 3 1 ~ 9 PCT/US94/10804
is added. The mixture is blended to uniformity at about 60C. The blend is
extruded to form desired shapes for their insertion into subgingival cavities.
A dentist inserts 0.05 mL of the extruded composition into a subgingival
cavity of a subject having adult periodontitis using cotton pliers. The
5 composition undergoes gradual degredation and does not need to be
removed. The result is a reduction in gingival inflammation and pocketing.
Example lll
The following is a representative example of a method of using peroral dosage
forms of azithromycin.
A human subject afflicted with adult periodontitis ingests à dose of 500
mg of azithromycin in the form of two ZithromaxTM capsules (250 mg of
azithromycin each) on a first day. For each of five days immediately
succeeding the first day, the subject ingests a dose of 250 mg azithromycin in
the form of one ZithromaxTM capsule per day. The result is a reduction in
15 gingival inflam"~a~ion and pocketing.
Example IV
The following is a representative example of a mouth rinse composition of this
invention.
comPonent Wt %
Azythromycin 0.1
EtOH (200 proof) 16.25
Surfactant (TWEEN 80) 0.12
Glycerin 1 0.
Saccharin 0.06
Flavor 0.041
F&DC Blue #1 ( 1 % soln) 0.022
F&DC Yellow#5 (1% soln) 0.018
Benzoic acid 0.0045
Sodium Benzoate 0.054
Water q.s.
A person introduces fifteen mL of the mouth rinse comprising
azithromycin to the oral cavity. The liquid is then agitated for 90 seco"ds
within the oral cavity to obtain a good distribution of the mouth rinse over thetissues of the oral cavity. Following agitation, the mouth rinse is expeclorated35 from the oral cavity. This proceedure is done twice per day;for total of ten
days. The result is reduced gingival inflammation and pocket depth.
While particular embodiments of this invention have bel n described, it
will be obvious to those skilled in the art that variousl changes and
modifications to this invention can be made without departing from the spirit
WO 95/99601 ` ~. 2 1 7 3 1 0 9 PCT/US9J/1080J
and scope of the invention. It is intended to cover, in the appended claims, allsuch modifications that are within the scope of this invention.
